July 25, 2024

Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

To describe cytokine release syndrome (CRS) associated with immune checkpoint inhibitors (ICIs) reported in the FDA Adverse Event Reporting System (FAERS).

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Xi et al. (Thu,) studied this question.

synapsesocial.com/papers/68e5f0a8b6db643587585667 https://doi.org/https://doi.org/10.1080/14740338.2024.2385489

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cytokine release syndrome in severe COVID-192020 · 2,033 citations
2Cancer statistics, 20232023 · 16,682 citations
3Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS2022 · 64 citations
4Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events2015 · 76 citations
5Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance2019 · 2,250 citations

Preguntar a la IA

Me gusta

Guardar